# Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

> **NCT00845429** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 729 (actual)

## Conditions studied

- Influenza
- Orthomyxoviruses
- Myxovirus Infection

## Interventions

- **BIOLOGICAL:** Influenza virus vaccine - cell based (2007-2008 Formulation)
- **BIOLOGICAL:** Influenza virus vaccine - cell-based (2007-2008 Formulation)
- **BIOLOGICAL:** Influenza virus vaccine (2007-2008 Formulation)

## Key facts

- **NCT ID:** NCT00845429
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-08
- **Final completion:** 2008-11
- **Target enrollment:** 729 (ACTUAL)
- **Last updated:** 2012-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845429, "Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00845429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*